文献速递妇科

二氧化硅阴道凝胶与短期高危人乳头瘤病毒DNA可检测性:一项随机对照试验

Silicon dioxide vaginal gel and short‐term high‐risk human papillomavirus DNA detectability: A randomized controlled trial
RSS 订阅 · Acta Obstetricia et Gynecologica Scandinavica · 2026-10-26

这项前瞻性、单中心、平行组、随机、开放标签对照试验纳入242例PCR确诊宫颈hrHPV感染且无立即治疗指征的女性,1:1随机接受3个月每日自我阴道凝胶治疗或单纯观察。3个月时凝胶组hrHPV DNA未检出18/99(18%)vs观察组23/109(21%),绝对风险差−2.9个百分点(95%CI −14至8;p=0.60);凝胶组患者报告不良事件更多(32/99[32%] vs 2/106[2%];绝对风险差30个百分点,95%CI 21至40;p<0.001),满意度两组均高但凝胶组较低。

要点

  • 3个月每日二氧化硅阴道凝胶未提高hrHPV DNA未检出比例(18% vs 21%,绝对风险差−2.9个百分点,95%CI −14至8;p=0.60)。
  • 凝胶组患者报告不良事件更频繁(32% vs 2%;绝对风险差30个百分点,95%CI 21至40;p<0.001)。
  • 两组满意度评分均高,但凝胶组低于观察组。

核心结论

  • 3个月每日阴道二氧化硅凝胶治疗与单纯观察相比未改善短期宫颈hrHPV DNA可检测性的丧失。
  • 该试验未重现既往产品相关研究提示的大幅短期病毒学获益。
  • findings不支持仅以促进短期hrHPV不可检出为目的常规使用该干预,尤其考虑到局部不良事件更频繁。

研究设计与样本

  • 前瞻性、单中心、平行组、随机、开放标签对照试验。
  • 纳入242例PCR确诊宫颈hrHPV感染且无立即治疗指征的女性,1:1随机分配至3个月每日自我阴道凝胶治疗组或单纯观察组,每组121例。
  • 主要结局为3个月时PCR检测宫颈hrHPV DNA不可检出;次要结局为随机研究期间患者报告满意度和不良事件。
  • 试验注册号:ClinicalTrials.gov,NCT05509413。
  • 研究时间为2022年11月至2025年1月,主要终点数据可获取于208例女性。

主要发现

  • 3个月时凝胶治疗组hrHPV DNA未检出18/99(18%),观察组23/109(21%);绝对风险差−2.9个百分点(95%CI −14至8;p=0.60)。
  • 事后调整敏感性分析未实质性改变主要比较的解释。
  • 凝胶治疗组患者报告不良事件32/99(32%),观察组2/106(2%);绝对风险差30个百分点(95%CI 21至40;p<0.001)。
  • 两组满意度评分均高,但凝胶治疗组较低。

临床怎么用

  • 原文结论指出, findings不支持仅以促进短期hrHPV不可检出为目的常规使用该干预,尤其考虑到局部不良事件更频繁。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In an independent randomized trial of 242 women with PCR-confirmed hrHPV infection, 3 months of silicon dioxide-based vaginal gel did not improve hrHPV DNA non-detectability compared with observation alone (18% vs. 21%). Patient-reported adverse events were more frequent with gel (32% vs. 2%), and overall patient satisfaction was lower. Abstract Introduction Intravaginal products, including silicon dioxide-based gels, are marketed to support short-term high-risk human papillomavirus (hrHPV) clearance or loss of detectability, but independent randomized evidence testing these short-term claims against observation is limited. We evaluated whether daily intravaginal silicon dioxide-based gel treatment increases the proportion of women with no detectable cervical hrHPV DNA compared with observation alone. Material and Methods This prospective, single-center, parallel-group, randomized, open-label controlled trial included women with PCR-confirmed cervical hrHPV infection and no indication for immediate treatment. Participants were randomized 1:1 to 3 months of self-administered daily intravaginal gel treatment or observation alone. The primary outcome was absence of detectable cervical hrHPV DNA by PCR at 3 months. Secondary outcomes during the randomized study period were patient-reported satisfaction and adverse events. Trial registration: ClinicalTrials.gov, NCT05509413, https://clinicaltrials.gov/study/NCT05509413. Results Between November 2022 and January 2025, 242 women were randomized, with 121 allocated to each group. Primary-endpoint data were available for 208 women. At 3 months, hrHPV DNA was not detected in 18/99 women (18%) in the gel treatment group and 23/109 women (21%) in the observation group (absolute risk difference −2.9 percentage points, 95% CI −14 to 8; p = 0.60). A reduced post hoc adjusted sensitivity analysis did not materially change the interpretation of the primary comparison. Patient-reported adverse events were more frequent in the gel treatment group than in the observation group (32/99 [32%] vs. 2/106 [2%]; absolute risk difference 30 percentage points, 95% CI 21 to 40; p < 0.001). Satisfaction scores were high in both groups but lower with gel treatment. Conclusions In this randomized trial, 3 months of daily intravaginal silicon dioxide-based gel treatment did not improve short-term loss of detectable cervical hrHPV DNA compared with observation alone. The trial did not reproduce the large short-term virologic benefit suggested by prior product-related studies. The findings do not support routine use of this intervention solely to promote short-term hrHPV non-detectability in women without an indication for immediate treatment, particularly given the higher frequency of local adverse events.

来源:Acta Obstetricia et Gynecologica Scandinavica,查看原文。版权归原作者所有。

引用

  1. Acta Obstetricia et Gynecologica Scandinavica:Silicon dioxide vaginal gel and short‐term high‐risk human papillomavirus DNA detectability: A randomized controlled trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。